VJDementia is committed to improving our service to you

Share this video  

VJDementia is committed to improving our service to you

ARUK 2019 | The heterogeneity of Alzheimer’s disease

Philip Scheltens • 19 Mar 2019
ARUK 2019
Alzheimer’s Disease Dementia
Biology

Philip Scheltens, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, speaks at the Alzheimer’s Research UK (ARUK) Conference 2019, held in Harrogate, UK. He discusses the heterogeneity of Alzheimer’s disease and how this may impact drug trials.

More from Philip Scheltens

3:28
Outcome measures in dementia studies
Philip Scheltens • 25 Jun 2017
1:53
Current approaches for the management of Alzheimer’s disease
Philip Scheltens • 29 May 2016
1:18
Declining dementia incidence
Philip Scheltens • 29 May 2016
2:45
Imaging of Alzheimer’s disease
Philip Scheltens • 29 May 2016

Related Videos

0:56
Blood-based biomarkers for treatment monitoring in Alzheimer’s disease
Suzanne Schindler • 19 Aug 2023
3:31
The Phase III LUCIDITY trial: a tau aggregation inhibitor in patients with Alzheimer’s disease
Sonya Miller • 17 Aug 2023
2:37
Time gap between amyloid- and tau-PET positivity in preclinical disease
Alexis Moscoso • 7 Aug 2023
2:41
Visual versus quantitative analysis of tau-PET
Alexis Moscoso • 7 Aug 2023
The content of VJDementia is intended for healthcare professionals